🚨 Aurobindo Pharma Gets USFDA Nod for Key Generic Drug Launch

$AUROPHARMA will be in focus today (5 June 2026) after receiving final approval from the US Food & Drug Administration (USFDA) for Tofacitinib Tablets (5 mg and 10 mg). The approved product is bioequivalent and therapeutically equivalent to Xeljanz, the reference listed drug of PF Prism CV. The company said the tablets will be manufactured at APL Healthcare Unit IV, its wholly owned subsidiary, with an immediate market launch planned. The approval strengthens Aurobindo Pharma's US generics portfolio and could support its growth in regulated markets. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.